Peritoneal dialysis (PD) patients treated with ACE inhibitors or angiotensin receptor blockers (ARBs) have a 62% reduced risk of death compared with PD patients not treated with these medications, after adjusting for age, BP, and other variables, according to a report in Nephrology Dialysis Transplantation (2008; published online ahead of print).